Johnson Health Tech .Co Second Quarter 2024 Earnings: Beats Expectations

Johnson Health Tech .Co (TWSE:1736) Second Quarter 2024 Results

Key Financial Results

• Revenue: NT$10.3b (up 19% from 2Q 2023).
• Net income: NT$292.1m (down 12% from 2Q 2023).
• Profit margin: 2.8% (down from 3.9% in 2Q 2023). The decrease in margin was driven by higher expenses.
• EPS: NT$0.96 (down from NT$1.10 in 2Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Johnson Health Tech .Co Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 5.0%. Earnings per share (EPS) also surpassed analyst estimates by 40%.

Looking ahead, revenue is forecast to grow 2.8% p.a. on average during the next 2 years, compared to a 9.8% growth forecast for the Leisure industry in Taiwan.

Performance of the Taiwanese Leisure industry.

The company's share price is broadly unchanged from a week ago.

Valuation

Our analysis of Johnson Health Tech .Co based on 6 different valuation metrics shows it might be overvalued. You can access our in-depth analysis and discover what the outlook is like for the stock by clicking here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.